Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study

被引:24
作者
West, Malcolm [1 ]
Kirby, Adrienne [2 ]
Stewart, Ralph A. [3 ]
Blankenberg, Stefan [4 ]
Sullivan, David [5 ]
White, Harvey D. [3 ]
Hunt, David [6 ]
Marschner, Ian [2 ]
Janus, Edward [7 ]
Kritharides, Leonard [8 ,9 ]
Watts, Gerald F. [10 ]
Simes, John [2 ]
Tonkin, Andrew M. [11 ]
机构
[1] Univ Queensland, Dept Med, Brisbane, Qld, Australia
[2] Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Sydney, NSW, Australia
[3] Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand
[4] Univ Heart & Vasc Ctr Hamburg, Hamburg, Germany
[5] Royal Prince Alfred Hosp, Dept Chem Pathol, Sydney, NSW, Australia
[6] Royal Melbourne Hosp, Cardiol Dept, Melbourne, Vic, Australia
[7] Univ Melbourne, Melbourne Med Sch, Western Hlth, Dept Med,Western Hlth Chron Dis Alliance, Melbourne, Vic, Australia
[8] Sydney Local Hlth Dist, Concord Repatriat Gen Hosp, Dept Cardiol, Sydney, NSW, Australia
[9] Univ Sydney, Fac Med, ANZAC Med Res Inst, Sydney, NSW, Australia
[10] Univ Western Australia, Fac Hlth & Med Sci, Sch Med, Perth, WA, Australia
[11] Monash Univ, Sch Publ Hlth & Prevent Med, Perth, WA, Australia
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2022年 / 11卷 / 05期
基金
英国医学研究理事会;
关键词
biomarkers; cardiovascular disease; chronic kidney disease; coronary disease; cystatin C; hydroxymethylglutaryl-CoA reductase inhibitors; risk assessment; CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; CYSTEINE PROTEASES; SERUM CREATININE; DEATH; EVENTS; ASSOCIATION; PRAVASTATIN; BIOMARKERS; STRATIFICATION;
D O I
10.1161/JAHA.121.020745
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long-term or is independent of renal function and other important biomarkers. METHODS AND RESULTS: Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow-up, 6 years) and long-term (median follow-up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR-creatinine, then GFR-creatinine-cystatin C). Over 6 years, in fully adjusted multivariable time-to-event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07-1.74; P=0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19-1.82; P<0.001). Over 16 years, the association of baseline cystatin C with coronary heart disease, cardiovascular, and all-cause mortality persisted (each P<0.001) and remained significant after adjustment for estimated GFR-creatinine-cystatin C. Cystatin C also predicted the development of chronic kidney disease for 6 years (odds ratio, 6.61; 95% CI, 4.28-10.20) independently of estimated GFR-creatinine and other risk factors. However, this association was no longer significant after adjustment for estimated GFR-creatinine-cystatin C. CONCLUSIONS: Cystatin C independently predicted major cardiovascular events, development of chronic kidney disease, and cardiovascular and all-cause mortality. Prediction of long-term mortality was independent of improved estimation of GFR. REGISTRATION: URL: https://anzctr.org.au; Unique identifier: ACTRN12616000535471.
引用
收藏
页数:26
相关论文
共 58 条
  • [1] Contribution of 30 Biomarkers to 10-Year Cardiovascular Risk Estimation in 2 Population Cohorts The MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project
    Blankenberg, Stefan
    Zeller, Tanja
    Saarela, Olli
    Havulinna, Aki S.
    Kee, Frank
    Tunstall-Pedoe, Hugh
    Kuulasmaa, Kari
    Yarnell, John
    Schnabel, Renate B.
    Wild, Philipp S.
    Muenzel, Thomas
    Lackner, Karl J.
    Tiret, Laurence
    Evans, Alun
    Salomaa, Veikko
    [J]. CIRCULATION, 2010, 121 (22) : 2388 - U57
  • [2] Emerging roles for cysteine proteases in human biology
    Chapman, HA
    Riese, RJ
    Shi, GP
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, 1997, 59 : 63 - 88
  • [3] Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis
    Chen, Shenghua
    Tang, Yangzhang
    Zhou, Xueyin
    [J]. BIOSCIENCE REPORTS, 2019, 39
  • [4] ALBUMINURIA REFLECTS WIDESPREAD VASCULAR DAMAGE - THE STENO HYPOTHESIS
    DECKERT, T
    FELDTRASMUSSEN, B
    BORCHJOHNSEN, K
    JENSEN, T
    KOFOEDENEVOLDSEN, A
    [J]. DIABETOLOGIA, 1989, 32 (04) : 219 - 226
  • [5] Impact of Kidney Function on Cardiovascular Risk and Mortality: A Comparison of South Asian and European Cohorts
    Eastwood, Sophie, V
    Chaturvedi, Nishi
    Sattar, Naveed
    Welsh, Paul, I
    Hughes, Alun D.
    Tillin, Therese
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2019, 50 (06) : 425 - 433
  • [6] Association Between Increased Levels of Cystatin C and the Development of Cardiovascular Events or Mortality: A Systematic Review and Meta-Analysis
    Einwoegerer, Caroline Fuchs
    Domingueti, Caroline Pereira
    [J]. ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2018, 111 (06) : 796 - 807
  • [7] K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword
    Eknoyan, G
    Levin, NW
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) : S14 - S266
  • [8] Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
    Gansevoort, Ron T.
    Correa-Rotter, Ricardo
    Hemmelgarn, Brenda R.
    Jafar, Tazeen H.
    Heerspink, Hiddo J. Lambers
    Mann, Johannes F.
    Matsushita, Kunihiro
    Wen, Chi Pang
    [J]. LANCET, 2013, 382 (9889) : 339 - 352
  • [9] Cystatin C as a predictor of cardiovascular outcomes in a hypertensive population
    Garcia-Carretero, R.
    Vigil-Medina, L.
    Barquero-Perez, O.
    Goya-Esteban, R.
    Mora-Jimenez, I.
    Soguero-Ruiz, C.
    Ramos-Lopez, J.
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2017, 31 (12) : 801 - 807
  • [10] Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
    Go, AS
    Chertow, GM
    Fan, DJ
    McCulloch, CE
    Hsu, CY
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) : 1296 - 1305